

# Union Calendar No. 196

112TH CONGRESS  
1ST SESSION

# H. R. 1254

[Report No. 112–295, Parts I and II]

To amend the Controlled Substances Act to place synthetic drugs in Schedule I.

---

## IN THE HOUSE OF REPRESENTATIVES

MARCH 30, 2011

Mr. DENT (for himself, Mr. MEEHAN, Mr. MARINO, Mr. PLATTS, Mr. BARLETTA, Mr. CUELLAR, Mrs. EMERSON, Mrs. BIGGERT, Mr. LATOURETTE, Mr. GIBSON, Mr. STIVERS, and Mr. REED) introduced the following bill; which was referred to the Committee on Energy and Commerce, and in addition to the Committee on the Judiciary, for a period to be subsequently determined by the Speaker, in each case for consideration of such provisions as fall within the jurisdiction of the committee concerned

NOVEMBER 22, 2011

Reported from the Committee on Energy and Commerce with an amendment

[Strike out all after the enacting clause and insert the part printed in *italic*]

NOVEMBER 22, 2011

Additional sponsors: Mr. HOLDEN, Mr. BOSWELL, Mr. LATHAM, Mr. LOEBSACK, Mr. DEFAZIO, Mr. DOLD, Mr. LANCE, Mr. MURPHY of Pennsylvania, Mrs. BONO MACK, Mr. MICHAUD, Ms. PINGREE of Maine, and Mr. GOWDY

NOVEMBER 22, 2011

Reported from the Committee on the Judiciary with an amendment, committed to the Committee of the Whole House on the State of the Union, and ordered to be printed

[Strike out all after the enacting clause and insert the part printed in **boldface roman**]

[For text of introduced bill, see copy of bill as introduced on March 30, 2011]

# **A BILL**

To amend the Controlled Substances Act to place synthetic  
drugs in Schedule I.

1 *Be it enacted by the Senate and House of Representa-*  
2 *tives of the United States of America in Congress assembled,*

3 **SECTION 1. SHORT TITLE.**

4 *This Act may be cited as the “Synthetic Drug Control*  
5 *Act of 2011”.*

6 **SEC. 2. ADDITION OF SYNTHETIC DRUGS TO SCHEDULE I**  
7 **OF THE CONTROLLED SUBSTANCES ACT.**

8 (a) *CANNABIMIMETIC AGENTS.*—*Schedule I, as set*  
9 *forth in section 202(c) of the Controlled Substances Act (21*  
10 *U.S.C. 812(c)) is amended by adding at the end the fol-*  
11 *lowing:*

12 “(d)(1) *Unless specifically exempted or unless listed in*  
13 *another schedule, any material, compound, mixture, or*  
14 *preparation which contains any quantity of*  
15 *cannabimimetic agents, or which contains their salts, iso-*  
16 *mers, and salts of isomers whenever the existence of such*  
17 *salts, isomers, and salts of isomers is possible within the*  
18 *specific chemical designation.*

19 “(2) *In paragraph (1):*

20 “(A) *The term ‘cannabimimetic agents’ means*  
21 *any substance that is a cannabinoid receptor type 1*  
22 *(CB1 receptor) agonist as demonstrated by binding*  
23 *studies and functional assays within any of the fol-*  
24 *lowing structural classes:*

1           “(i) 2-(3-hydroxycyclohexyl)phenol with  
2 substitution at the 5-position of the phenolic ring  
3 by alkyl or alkenyl, whether or not substituted on  
4 the cyclohexyl ring to any extent.

5           “(ii) 3-(1-naphthoyl)indole or 3-(1-  
6 naphthylmethane)indole by substitution at the  
7 nitrogen atom of the indole ring, whether or not  
8 further substituted on the indole ring to any ex-  
9 tent, whether or not substituted on the naphthoyl  
10 or naphthyl ring to any extent.

11          “(iii) 3-(1-naphthoyl)pyrrole by substi-  
12 tution at the nitrogen atom of the pyrrole ring,  
13 whether or not further substituted in the pyrrole  
14 ring to any extent, whether or not substituted on  
15 the naphthoyl ring to any extent.

16          “(iv) 1-(1-naphthylmethylene)indene by sub-  
17 stitution of the 3-position of the indene ring,  
18 whether or not further substituted in the indene  
19 ring to any extent, whether or not substituted on  
20 the naphthyl ring to any extent.

21          “(v) 3-phenylacetylindole or 3-benzoylindole  
22 by substitution at the nitrogen atom of the indole  
23 ring, whether or not further substituted in the  
24 indole ring to any extent, whether or not sub-  
25 stituted on the phenyl ring to any extent.

1           “(B) Such term includes—

2                   “(i)     5-(1,1-dimethylheptyl)-2-[(1R,3S)-3-  
3                   hydroxycyclohexyl]-phenol (CP-47,497);

4                   “(ii)    5-(1,1-dimethyloctyl)-2-[(1R,3S)-3-  
5                   hydroxycyclohexyl]-phenol (cannabicyclohexanol  
6                   or CP-47,497 C8-homolog);

7                   “(iii)  1-pentyl-3-(1-naphthoyl)indole (JWH-  
8                   018 and AM678);

9                   “(iv)  1-butyl-3-(1-naphthoyl)indole (JWH-  
10                  073);

11                  “(v)  1-hexyl-3-(1-naphthoyl)indole (JWH-  
12                  019);

13                  “(vi)  1-[2-(4-morpholinyl)ethyl]-3-(1-naph-  
14                  thoyl)indole (JWH-200);

15                  “(vii)                           1-pentyl-3-(2-  
16                  methoxyphenylacetyl)indole (JWH-250);

17                  “(viii)                           1-pentyl-3-[1-(4-  
18                  methoxynaphthoyl)]indole (JWH-081);

19                  “(ix)                   1-pentyl-3-(4-methyl-1-naph-  
20                  thoyl)indole (JWH-122);

21                  “(x)  1-pentyl-3-(4-chloro-1-naphthoyl)indole  
22                  (JWH-398);

23                  “(xi)                   1-(5-fluoropentyl)-3-(1-naph-  
24                  thoyl)indole (AM2201);

1                   “(xii)                   1-(5-fluoropentyl)-3-(2-  
2                   iodobenzoyl)indole (AM694);

3                   “(xiii)                   1-pentyl-3-[(4-methoxy)-ben-  
4                   zoyl]indole (SR-19 and RCS-4);

5                   “(xiv)                   1-cyclohexylethyl-3-(2-  
6                   methoxyphenylacetyl)indole (SR-18 and RCS-8);

7                   and

8                   “(xv)                   1-pentyl-3-(2-  
9                   chlorophenylacetyl)indole (JWH-203).”.

10           (b) *OTHER DRUGS.*—Schedule I of section 202(c) of  
11 *the Controlled Substances Act (21 U.S.C. 812(c)) is amend-*  
12 *ed in subsection (c) by adding at the end the following:*

13                   “(18) 4-methylmethcathinone (Mephedrone).

14                   “(19) 3,4-methylenedioxyprovalerone (MDPV).

15                   “(20)                   3,4-methylenedioxyethcathinone  
16                   (methylone).

17                   “(21) Naphthylpyrovalerone (naphyrone).

18                   “(22) 4-fluoromethcathinone (flephedrone).

19                   “(23) 4-methoxymethcathinone (methedrone; Bk-  
20                   PMMA).

21                   “(24) Ethcathinone (N-Ethylcathinone).

22                   “(25) 3,4-methylenedioxyethcathinone (ethylone).

23                   “(26)                   Beta-keto-N-methyl-3,4-  
24                   benzodioxypolybutanamine (butylone).

25                   “(27) N,N-dimethylcathinone (metamfepramone).

1           “(28) *Alpha-pyrrolidinopropiophenone (alpha-*  
2           *PPP).*”

3           “(29) *4-methoxy-alpha-pyrrolidinopropiophenone*  
4           *(MOPPP).*”

5           “(30)                                 *3,4-methylenedioxy-alpha-*  
6           *pyrrolidinopropiophenone (MDPPP).*”

7           “(31) *Alpha-pyrrolidinovalerophenone (alpha-*  
8           *PVP).*”

9           “(32)   *6,7-dihydro-5H-indeno-(5,6-d)-1,3-dioxol-*  
10          *6-amine) (MDAI).*”

11          “(33) *3-fluoromethcathinone.*”

12          “(34)           *4'-Methyl- $\alpha$ -pyrrolidinobutiophenone*  
13          *(MPBP).*”.

14   **SEC. 3. TEMPORARY SCHEDULING TO AVOID IMMINENT**  
15                                 **HAZARDS TO PUBLIC SAFETY EXPANSION.**

16          *Section 201(h)(2) of the Controlled Substances Act (21*  
17          *U.S.C. 811(h)(2)) is amended—*

18                 (1) *by striking “one year” and inserting “2*  
19                 *years”; and*

20                 (2) *by striking “six months” and inserting “1*  
21                 *year”.*

22   **SECTION 1. SHORT TITLE.**

23                 **This Act may be cited as the “Synthetic**  
24                 **Drug Control Act of 2011”.**

1 SEC. 2. ADDITION OF SYNTHETIC DRUGS TO SCHEDULE I  
2 OF THE CONTROLLED SUBSTANCES ACT.

3 (a) CANNABIMIMETIC AGENTS.—Schedule I,  
4 as set forth in section 202(c) of the Controlled  
5 Substances Act (21 U.S.C. 812(c)) is amended  
6 by adding at the end the following:

7 “(d)(1) Unless specifically exempted or un-  
8 less listed in another schedule, any material,  
9 compound, mixture, or preparation which  
10 contains any quantity of cannabimimetic  
11 agents, or which contains their salts, isomers,  
12 and salts of isomers whenever the existence  
13 of such salts, isomers, and salts of isomers is  
14 possible within the specific chemical designa-  
15 tion.

16 “(2) In paragraph (1):

17 “(A) The term ‘cannabimimetic  
18 agents’ means any substance that is a  
19 cannabinoid receptor type 1 (CB1 recep-  
20 tor) agonist as demonstrated by binding  
21 studies and functional assays within any  
22 of the following structural classes:

23 “(i) 2-(3-hydroxycyclohexyl)phenol  
24 with substitution at the 5-position of  
25 the phenolic ring by alkyl or alkenyl,



1           “(v) 3-phenylacetylindole or 3-  
2 benzoylindole by substitution at the  
3 nitrogen atom of the indole ring,  
4 whether or not further substituted in  
5 the indole ring to any extent, whether  
6 or not substituted on the phenyl ring  
7 to any extent.

8           “(B) Such term includes—

9           “(i)           5-(1,1-dimethylheptyl)-2-  
10 [(1R,3S)-3-hydroxycyclohexyl]-phenol  
11 (CP-47,497);

12           “(ii)          5-(1,1-dimethyloctyl)-2-  
13 [(1R,3S)-3-hydroxycyclohexyl]-phenol  
14 (cannabicyclohexanol or CP-47,497  
15 C8-homolog);

16           “(iii)          1-pentyl-3-(1-naph-  
17 thoyl)indole (JWH-018 and AM678);

18           “(iv) 1-butyl-3-(1-naphthoyl)indole  
19 (JWH-073);

20           “(v) 1-hexyl-3-(1-naphthoyl)indole  
21 (JWH-019);

22           “(vi) 1-[2-(4-morpholinyl)ethyl]-3-  
23 (1-naphthoyl)indole (JWH-200);

- 1           “(vii)                           **1-pentyl-3-(2-**  
2           **methoxyphenylacetyl)indole (JWH-**  
3           **250);**
- 4           “(viii)                           **1-pentyl-3-[1-(4-**  
5           **methoxynaphthoyl)]indole (JWH-081);**
- 6           “(ix)   **1-pentyl-3-(4-methyl-1-naph-**  
7           **thoyl)indole (JWH-122);**
- 8           “(x)   **1-pentyl-3-(4-chloro-1-naph-**  
9           **thoyl)indole (JWH-398);**
- 10          “(xi)   **1-(5-fluoropentyl)-3-(1-naph-**  
11          **thoyl)indole (AM2201);**
- 12          “(xii)           **1-(5-fluoropentyl)-3-(2-**  
13          **iodobenzoyl)indole (AM694);**
- 14          “(xiii) **1-pentyl-3-[(4-methoxy)-ben-**  
15          **zoyl]indole (SR-19 and RCS-4);**
- 16          “(xiv)           **1-cyclohexylethyl-3-(2-**  
17          **methoxyphenylacetyl)indole (SR-18**  
18          **and RCS-8); and**
- 19          “(xv)                           **1-pentyl-3-(2-**  
20          **chlorophenylacetyl)indole (JWH-**  
21          **203).”.**

22           **(b) OTHER DRUGS.—Schedule I of section**  
23           **202(c) of the Controlled Substances Act (21**  
24           **U.S.C. 812(c)) is amended in subsection (c) by**  
25           **adding at the end the following:**



- 1           **“(30)                           3,4-methylenedioxy-**  
2 **alphapyrrolidinopropiophenone**  
3 **(MDPPP).**
- 4           **“(31) Alpha-pyrrolidinovalerophenone**  
5 **(alpha-PVP).**
- 6           **“(32) 6,7-dihydro-5H-indeno-(5,6-d)-1,3-**  
7 **dioxol-6-amine) (MDAI).**
- 8           **“(33) 3-fluoromethcathinone.**
- 9           **“(34)                           4'-Methyl- $\alpha$ -**  
10 **pyrrolidinobutiophenone (MPBP).**
- 11           **“(35)                           2-(2,5-Dimethoxy-4-**  
12 **ethylphenyl)ethanamine (2C-E).**
- 13           **“(36)                           2-(2,5-Dimethoxy-4-**  
14 **methylphenyl)ethanamine (2C-D).**
- 15           **“(37)                           2-(4-Chloro-2,5-**  
16 **dimethoxyphenyl)ethanamine (2C-C).**
- 17           **“(38)                           2-(4-Iodo-2,5-**  
18 **dimethoxyphenyl)ethanamine (2C-I).**
- 19           **“(39)                           2-[4-(Ethylthio)-2,5-**  
20 **dimethoxyphenyl]ethanamine (2C-T-2).**
- 21           **“(40)                           2-[4-(Isopropylthio)-2,5-**  
22 **dimethoxyphenyl]ethanamine (2C-T-4).**
- 23           **“(41)                           2-(2,5-**  
24 **Dimethoxyphenyl)ethanamine (2C-H).**

1           **“(42)           2-(2,5-Dimethoxy-4-nitro-**  
2           **phenyl)ethanamine (2C-N).**

3           **“(43)           2-(2,5-Dimethoxy-4-(n)-**  
4           **propylphenyl)ethanamine (2C-P).”.**

5   **SEC. 3. TEMPORARY SCHEDULING TO AVOID IMMINENT**  
6           **HAZARDS TO PUBLIC SAFETY EXPANSION.**

7           **Section 201(h)(2) of the Controlled Sub-**  
8           **stances Act (21 U.S.C. 811(h)(2)) is amended—**

9           **(1) by striking “one year” and insert-**  
10          **ing “2 years”; and**

11          **(2) by striking “six months” and in-**  
12          **serting “1 year”.**



Union Calendar No. 196

112<sup>TH</sup> CONGRESS  
1<sup>ST</sup> Session

**H. R. 1254**

[Report No. 112-295, Parts I and II]

---

---

**A BILL**

To amend the Controlled Substances Act to place  
synthetic drugs in Schedule I.

---

---

NOVEMBER 22, 2011

Reported from the Committee on Energy and Commerce  
with an amendment

NOVEMBER 22, 2011

Reported from the Committee on the Judiciary with an  
amendment, committed to the Committee of the Whole  
House on the State of the Union, and ordered to be  
printed